Tailoring Ras-pathway - Inhibitor combinations for cancer therapy

Drug Resistance Updates

Volumn 8, Issue 6, 2005, Pages 369-380

  Blum, Roy ^a   Kloog, Yoel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Combinatorial Ras therapy; Oncogene; Ras; Ras pathways

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; BEVACIZUMAB; BIM 46228; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; LONAFARNIB; MELPHALAN; PACLITAXEL; PAMIDRONIC ACID; PERIFOSINE; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TEMOZOLOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; ZOLEDRONIC ACID;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CLINICAL TRIAL; GLYCOLYSIS; HUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

EID: 33644815892     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2005.11.002     Document Type: Article

References (149)

1. A.A. Adjei, J.N. Davis, L.M. Bruzek, C. Erlichman, and S.H. Kaufmann Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines Clin. Cancer Res. 7 2001 1438 1445
2. A. Agathanggelou, W.N. Cooper, and F. Latif Role of the Ras-association domain family 1 tumor suppressor gene in human cancers Cancer Res. 65 2005 3497 3508
3. M. Alsina, R. Fonseca, E.F. Wilson, A.N. Belle, E. Gerbino, T. Price-Troska, R.M. Overton, G. Ahmann, L.M. Bruzek, A.A. Adjei, S.H. Kaufmann, J.J. Wright, D. Sullivan, B. Djulbegovic, A.B. Cantor, P.R. Greipp, W.S. Dalton, and S.M. Sebti Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma Blood 103 2004 3271 3277
4. K.I. Amiri, and A. Richmond Role of nuclear factor-kappa B in melanoma Cancer Metastasis Rev. 24 2005 301 313
5. K. Aoki, S. Ohnami, and T. Yoshida Suppression of pancreatic and colon cancer cells by antisense K-ras RNA expression vectors Methods Mol. Med. 106 2005 193 204
6. A. Awada, A. Hendlisz, T. Gil, S. Bartholomeus, M. Mano, D. de Valeriola, D. Strumberg, E. Brendel, C.G. Haase, B. Schwartz, and M. Piccart Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours Br. J. Cancer 92 2005 1855 1861
7. P. Bachireddy, P.K. Bendapudi, and D.W. Felsher Getting at MYC through RAS Clin. Cancer Res. 11 2005 4278 4281
8. N. Bardeesy, M. Kim, J. Xu, R.S. Kim, Q. Shen, M.W. Bosenberg, W.H. Wong, and L. Chin Role of epidermal growth factor receptor signaling in RAS-driven melanoma Mol. Cell. Biol. 25 2005 4176 4188
9. G. Behre, A.J. Whitmarsh, M.P. Coghlan, T. Hoang, C.L. Carpenter, D.E. Zhang, R.J. Davis, and D.G. Tenen c-Jun is a JNK-independent coactivator of the PU.1 transcription factor J. Biol. Chem. 274 1999 4939 4946
10. E. Berkovich, and D. Ginsberg Ras induces elevation of E2F-1 mRNA levels J. Biol. Chem. 276 2001 42851 42856
11. V. Besset, R.P. Scott, and C.F. Ibanez Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase J. Biol. Chem. 275 2000 39159 39166
12. R. Bianco, R. Caputo, V. Damiano, S. De Placido, C. Ficorella, S. Agrawal, A.R. Bianco, F. Ciardiello, and G. Tortora Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer Clin. Cancer Res. 10 2004 4858 4864
13. C. Blancher, J.W. Moore, N. Robertson, and A.L. Harris Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway Cancer Res. 61 2001 7349 7355
14. R. Blum, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, and Y. Kloog Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death Cancer Res. 65 2005 999 1006
15. B. Boettner, and L. Van Aelst The RASputin effect Genes Dev. 16 2002 2033 2038
16. P. Borst, and S. Rottenberg Cancer cell death by programmed necrosis? Drug Resist. Update 7 2004 321 324
17. H.J. Broxterman, and N.H. Georgopapadakou Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations Drug Resist. Update 8 2005 183 197
18. T.R. Brummelkamp, R. Bernards, and R. Agami Stable suppression of tumorigenicity by virus-mediated RNA interference Cancer Cell. 2 2002 243 247
19. A. Burchert, Y. Wang, D. Cai, N. von Bubnoff, P. Paschka, S. Muller-Brusselbach, O.G. Ottmann, J. Duyster, A. Hochhaus, and A. Neubauer Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development Leukemia 19 2005 1774 1782
20. S.L. Campbell, R. Khosravi-Far, K.L. Rossman, G.J. Clark, and C.J. Der Increasing complexity of Ras signaling Oncogene 17 1998 1395 1413
21. M. Caraglia, A.M. D'Alessandro, M. Marra, G. Giuberti, G. Vitale, C. Viscomi, A. Colao, S.D. Prete, P. Tagliaferri, P. Tassone, A. Budillon, S. Venuta, and A. Abbruzzese The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate Oncogene 23 2004 6900 6913
22. B.A. Centeno, S.A. Enkemann, D. Coppola, S. Huntsman, G. Bloom, and T.J. Yeatman Classification of human tumors using gene expression profiles obtained after microarray analysis of fine-needle aspiration biopsy samples Cancer 105 2005 101 109
23. L.M. Chen, H.Y. Le, R.Y. Qin, M. Kumar, Z.Y. Du, R.J. Xia, and J. Deng Reversal of the phenotype by K-rasval12 silencing mediated by adenovirus-delivered siRNA in human pancreatic cancer cell line Panc-1 World J. Gastroenterol. 11 2005 831 838
24. H. Chong, H.G. Vikis, and K.L. Guan Mechanisms of regulating the Raf kinase family Cell. Signal. 15 2003 463 469
25. S. Cleator, and A. Ashworth Molecular profiling of breast cancer: clinical implications Br. J. Cancer 90 2004 1120 1124
26. K.D. Corbett, and T. Alber The many faces of Ras: recognition of small GTP-binding proteins Trends Biochem. Sci. 26 2001 710 716
27. J. Cortes, M. Albitar, D. Thomas, F. Giles, R. Kurzrock, A. Thibault, W. Rackoff, C. Koller, S. O'Brien, G. Garcia-Manero, M. Talpaz, and H. Kantarjian Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies Blood 101 2003 1692 1697
28. J. Cortes, and H. Kantarjian New targeted approaches in chronic myeloid leukemia J. Clin. Oncol. 23 2005 6316 6324
29. A.D. Cox, and C.J. Der Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta 1333 1997 F51 F71
30. A.D. Cox, and C.J. Der Farnesyltransferase inhibitors: promises and realities Curr. Opin. Pharmacol. 2 2002 388 393
31. A.D. Cox, and C.J. Der Ras family signaling: therapeutic targeting Cancer Biol. Ther. 1 2002 599 606
32. L.C. Crossman, T. O'Hare, T. Lange, S.G. Willis, E.P. Stoffregen, A.S. Corbin, S.G. O'Brien, M.C. Heinrich, B.J. Druker, P.G. Middleton, and M.W. Deininger A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib Leukemia 19 2005 1859 1862
33. C.V. Dang c-Myc target genes involved in cell growth, apoptosis, and metabolism Mol. Cell. Biol. 19 1999 1 11
34. E. David, S.Y. Sun, E.K. Waller, J. Chen, F.R. Khuri, and S. Lonial The combination of the Farnesyl transferase inhibitor (Lonafarnib) and the proteasome inhibitor (Bortezomib) induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT Blood 2005
35. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
36. C.M. D'Cruz, E.J. Gunther, R.B. Boxer, J.L. Hartman, L. Sintasath, S.E. Moody, J.D. Cox, S.I. Ha, G.K. Belka, A. Golant, R.D. Cardiff, and L.A. Chodosh c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations Nat. Med. 7 2001 235 239
37. G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, and P.J. Roberts Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 347 2002 472 480
38. J. Downward Targeting RAS signalling pathways in cancer therapy Nat. Rev. Cancer 3 2003 11 22
39. M.A. Dressman, A. Baras, R. Malinowski, L.B. Alvis, I. Kwon, T.M. Walz, and M.H. Polymeropoulos Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer Cancer Res. 63 2003 2194 2199
40. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, J.M. Ford, N.B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, and C.L. Sawyers Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
41. G. Elad-Sfadia, R. Haklai, E. Balan, and Y. Kloog Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity J. Biol. Chem. 279 2004 34922 34930
42. G. Elad-Sfadia, R. Haklai, E. Ballan, H.J. Gabius, and Y. Kloog Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase J. Biol. Chem. 277 2002 37169 37175
43. R. Elkon, C. Linhart, R. Sharan, R. Shamir, and Y. Shiloh Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells Genome Res. 13 2003 773 780
44. L.M. Facchini, and L.Z. Penn The molecular role of Myc in growth and transformation: recent discoveries lead to new insights FASEB J. 12 1998 633 651
45. L.A. Feig Ral-GTPases: approaching their 15 min of fame Trends Cell. Biol. 13 2003 419 425
46. E. Feinstein Ral-GTPases: good chances for a long-lasting fame Oncogene 24 2005 326 328
47. E.J. Feldman Farnesyltransferase inhibitors in myelodysplastic syndrome Curr. Hematol. Rep. 4 2005 186 190
48. J.B. Fleming, G.L. Shen, S.E. Holloway, M. Davis, and R.A. Brekken Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy Mol. Cancer Res. 3 2005 413 423
49. M. Gana-Weisz, R. Haklai, D. Marciano, Y. Egozi, G. Ben Baruch, and Y. Kloog The Ras antagonist S-farnesyl thiosalicylic acid induces inhibition of MAPK activation Biochem. Biophys. Res. Commun. 239 1997 900 904
50. G. Garcea, C.P. Neal, C.J. Pattenden, W.P. Steward, and D.P. Berry Molecular prognostic markers in pancreatic cancer: a systematic review Eur. J. Cancer 41 2005 2213 2236
51. P. Ghaneh, A. Kawesha, J.D. Evans, and J.P. Neoptolemos Molecular prognostic markers in pancreatic cancer J. Hepatobiliary Pancreat. Surg. 9 2002 1 11
52. G. Giaccone, R.S. Herbst, C. Manegold, G. Scagliotti, R. Rosell, and V. Miller Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J. Clin. Oncol. 22 2004 777 784
53. A. Goga, J. McLaughlin, D.E. Afar, D.C. Saffran, and O.N. Witte Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene Cell 82 1995 981 988
54. J. Gotlib Farnesyltransferase inhibitor therapy in acute myelogenous leukemia Curr. Hematol. Rep. 4 2005 77 84
55. S. Gruvberger, M. Ringner, Y. Chen, S. Panavally, L.H. Saal, A. Borg, M. Ferno, C. Peterson, and P.S. Meltzer Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns Cancer Res. 61 2001 5979 5984
56. K.L. Guan, C. Figueroa, T.R. Brtva, T. Zhu, J. Taylor, T.D. Barber, and A.B. Vojtek Negative regulation of the serine/threonine kinase B-Raf by Akt J. Biol. Chem. 275 2000 27354 27359
57. J. Halaschek-Wiener, Y. Kloog, V. Wacheck, and B. Jansen Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo J. Invest. Dermatol. 120 2003 109 115
58. R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, V. Miller, and C. Manegold Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J. Clin. Oncol. 22 2004 785 794
59. R.S. Herbst, D.H. Johnson, E. Mininberg, D.P. Carbone, T. Henderson, and E.S. Kim Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J. Clin. Oncol. 23 2005 2544 2555
60. R.S. Herbst, D. Prager, R. Hermann, L. Fehrenbacher, B.E. Johnson, A. Sandler, M.G. Kris, H.T. Tran, P. Klein, X. Li, D. Ramies, D.H. Johnson, and V.A. Miller TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J. Clin. Oncol. 23 2005 5892 5899
61. H. Hu, J.M. Bliss, Y. Wang, and J. Colicelli RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration Curr. Biol. 15 2005 815 823
62. E. Huang, S. Ishida, J. Pittman, H. Dressman, A. Bild, M. Kloos, M. D'Amico, R.G. Pestell, M. West, and J.R. Nevins Gene expression phenotypic models that predict the activity of oncogenic pathways Nat. Genet. 34 2003 226 230
63. M. Janulis, S. Silberman, A. Ambegaokar, J.S. Gutkind, and R.M. Schultz Role of mitogen-activated protein kinases and c-Jun/AP-1 trans-activating activity in the regulation of protease mRNAs and the malignant phenotype in NIH 3T3 fibroblasts J. Biol. Chem. 274 1999 801 813
64. D.H. Johnson, L. Fehrenbacher, W.F. Novotny, R.S. Herbst, J.J. Nemunaitis, D.M. Jablons, C.J. Langer, R.F. DeVore 3rd, J. Gaudreault, L.A. Damico, E. Holmgren, and F. Kabbinavar Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J. Clin. Oncol. 22 2004 2184 2191
65. W.G. Kaelin Jr. E2F1 as a target: promoter-driven suicide and small molecule modulators Cancer Biol. Ther. 2 2003 S48 S54
66. M.D. Kane Technical issues in DNA microarray production and utilization: impact on clinical research Expert Rev. Mol. Diagn. 5 2005 649 654
67. A. Karlsson, S. Giuriato, F. Tang, J. Fung-Weier, G. Levan, and D.W. Felsher Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations Blood 101 2003 2797 2803
68. H. Kawasaki, T. Moriguchi, S. Matsuda, H.Z. Li, S. Nakamura, S. Shimohama, J. Kimura, Y. Gotoh, and E. Nishida Ras-dependent and Ras-independent activation pathways for the stress-activated-protein-kinase cascade Eur. J. Biochem. 241 1996 315 321
69. A. Khwaja, K. Lehmann, B.M. Marte, and J. Downward Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway J. Biol. Chem. 273 1998 18798 18801
70. E.S. Kim, M.S. Kies, F.V. Fossella, B.S. Glisson, S. Zaknoen, and P. Statkevich Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma Cancer 104 2005 561 569
71. J. Kim, J. Seong, and S.H. Kim Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma Ann. N.Y. Acad. Sci. 1030 2004 95 102
72. Y. Kloog, and A.D. Cox Ras inhibitors: potential for cancer therapeutics Mol. Med. Today 6 2000 398 402
73. P. Korkolopoulou, E. Patsouris, A.E. Konstantinidou, P.M. Pavlopoulos, N. Kavantzas, E. Boviatsis, I. Thymara, M. Perdiki, E. Thomas-Tsagli, D. Angelidakis, D. Rologis, and D. Sakkas Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis Neuropathol. Appl. Neurobiol. 30 2004 267 278
74. V.N. Kristensen, T. Sorlie, J. Geisler, A. Langerod, N. Yoshimura, R. Karesen, N. Harada, P.E. Lonning, and A.L. Borresen-Dale Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications Clin. Cancer Res. 11 2005 878s 883s
75. D.W. Leaman, S. Leung, X. Li, and G.R. Stark Regulation of STAT-dependent pathways by growth factors and cytokines FASEB J. 10 1996 1578 1588
76. P.F. Lebowitz, and G.C. Prendergast Non-Ras targets of farnesyltransferase inhibitors: focus on Rho Oncogene 17 1998 1439 1445
77. H.Y. Lee, H. Moon, K.H. Chun, Y.S. Chang, K. Hassan, L. Ji, R. Lotan, F.R. Khuri, and W.K. Hong Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells J. Natl. Cancer Inst. 96 2004 1536 1548
78. J.W. Lee, Y.H. Soung, S.Y. Kim, H.W. Lee, W.S. Park, S.W. Nam, S.H. Kim, J.Y. Lee, N.J. Yoo, and S.H. Lee PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas Oncogene 24 2005 1477 1480
79. S.R. Lee, J.H. Park, E.K. Park, C.H. Chung, S.S. Kang, and O.S. Bang Akt-induced promotion of cell-cycle progression at G(2)/M phase involves upregulation of NF-Y binding activity in PC12 cells J. Cell. Physiol. 205 2005 270 277
80. A. Levitzki EGF receptor as a therapeutic target Lung Cancer 41 Suppl. 1 2003 S9 S14
81. A. Levitzki Protein kinase inhibitors as a therapeutic modality Acc. Chem. Res. 36 2003 462 469
82. J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, and S.I. Wang PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947
83. V.S. Li, C.W. Wong, T.L. Chan, A.S. Chan, W. Zhao, K.M. Chu, S. So, X. Chen, S.T. Yuen, and S.Y. Leung Mutations of PIK3CA in gastric adenocarcinoma BMC Cancer 5 2005 29
84. I. Lopez, E.C. Mak, J. Ding, H.E. Hamm, and J.W. Lomasney A novel bifunctional phospholipase c that is regulated by Galpha 12 and stimulates the Ras/mitogen-activated protein kinase pathway J. Biol. Chem. 276 2001 2758 2765
85. D.J. Manalo, A. Rowan, T. Lavoie, L. Natarajan, B.D. Kelly, S.Q. Ye, J.G. Garcia, and G.L. Semenza Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1 Blood 105 2005 659 669
86. A.I. Marcus, J. Zhou, A. O'Brate, E. Hamel, J. Wong, M. Nivens, A. El-Naggar, T.P. Yao, F.R. Khuri, and P. Giannakakou The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase Cancer Res. 65 2005 3883 3893
87. S.A. Matheny, C. Chen, R.L. Kortum, G.L. Razidlo, R.E. Lewis, and M.A. White Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP Nature 427 2004 256 260
88. A. McFall, A. Ulku, Q.T. Lambert, A. Kusa, K. Rogers-Graham, and C.J. Der Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase Mol. Cell. Biol. 21 2001 5488 5499
89. A.S. Merseburger, M.A. Kuczyk, J. Serth, C. Bokemeyer, D.Y. Young, L. Sun, R.R. Connelly, D.G. McLeod, F.K. Mostofi, S.K. Srivastava, A. Stenzl, J.W. Moul, and I.A. Sesterhenn Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues Oncol. Rep. 10 2003 223 228
90. M.E. Minard, L.S. Kim, J.E. Price, and G.E. Gallick The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression Breast Cancer Res. Treat. 84 2004 21 32
91. N. Mitin, K.L. Rossman, and C.J. Der Signaling interplay in Ras superfamily function Curr. Biol. 15 2005 R563 R574
92. M.M. Moasser, L. Sepp-Lorenzino, N.E. Kohl, A. Oliff, A. Balog, D.S. Su, S.J. Danishefsky, and N. Rosen Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones Proc. Natl. Acad. Sci. U.S.A. 95 1998 1369 1374
93. H. Momota, E. Nerio, and E.C. Holland Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo Cancer Res. 65 2005 7429 7435
94. M. Moore, H.W. Hirte, L. Siu, A. Oza, S.J. Hotte, O. Petrenciuc, F. Cihon, C. Lathia, and B. Schwartz Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors Ann. Oncol. 16 2005 1688 1694
95. S. Nagafuchi, H. Katsuta, Y. Ohno, Y. Inoue, K. Shimoda, and K. Kogawa Mitogen-activated protein kinase pathway controls autoimmune regulator (AIRE) gene expression in granulo-monocyte colony stimulating factor (GM-CSF)-stimulated myelomonocytic leukemia OTC-4 cells Immunol. Lett. 99 2005 130 135
96. J.R. Nevins The Rb/E2F pathway and cancer Hum. Mol. Genet. 10 2001 699 703
97. M.E. Pacold, S. Suire, O. Perisic, S. Lara-Gonzalez, C.T. Davis, E.H. Walker, P.T. Hawkins, L. Stephens, J.F. Eccleston, and R.L. Williams Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma Cell 103 2000 931 943
98. S. Pelengaris, M. Khan, and G. Evan c-MYC: more than just a matter of life and death Nat. Rev. Cancer 2 2002 764 776
99. R. Perez-Soler, A. Chachoua, L.A. Hammond, E.K. Rowinsky, M. Huberman, D. Karp, J. Rigas, G.M. Clark, P. Santabarbara, and P. Bonomi Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J. Clin. Oncol. 22 2004 3238 3247
100. P. Porcu Profiling is a good thing (at least in the clinic) Blood 105 2005 1843
101. S. Potempa, and A.J. Ridley Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly Mol. Biol. Cell. 9 1998 2185 2200
102. M. Praskova, A. Khoklatchev, S. Ortiz-Vega, and J. Avruch Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras Biochem. J. 381 2004 453 462
103. G.P. Prevost, A. Pradines, M.C. Brezak, M.O. Lonchampt, I. Viossat, I. Ader, C. Toulas, P. Kasprzyk, T. Gordon, G. Favre, and B. Morgan Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228 Int. J. Cancer 91 2001 718 722
104. E. Procko, and S.R. McColl Leukocytes on the move with phosphoinositide 3-kinase and its downstream effectors Bioessays 27 2005 153 163
105. R. Ravi, and A. Bedi NF-kappaB in cancer - a friend turned foe Drug Resist. Update 7 2004 53 67
106. H.P. Reusch, S. Zimmermann, M. Schaefer, M. Paul, and K. Moelling Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells J. Biol. Chem. 276 2001 33630 33637
107. C.W. Reuter, M.A. Morgan, and L. Bergmann Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96 2000 1655 1669
108. H. Richly, P. Kupsch, K. Passage, M. Grubert, R.A. Hilger, R. Voigtmann, B. Schwartz, E. Brendel, O. Christensen, C.G. Haase, and D. Strumberg Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer Int. J. Clin. Pharmacol. Ther. 42 2004 650 651
109. S. Roche, J. McGlade, M. Jones, G.D. Gish, T. Pawson, and S.A. Courtneidge Requirement of phospholipase C gamma, the tyrosine phosphatase Syp and the adaptor proteins Shc and Nck for PDGF-induced DNA synthesis: evidence for the existence of Ras-dependent and Ras-independent pathways EMBO J. 15 1996 4940 4948
110. P. Rodriguez Viciana, P.H. Warne, A. Khwaja, B.M. Marte, D. Pappin, P. Das, M.D. Waterfield, A. Ridley, and J. Downward Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras Cell 89 1997 457 467
111. A. Rody, S. Loibl, G. von Minckwitz, and M. Kaufmann Use of goserelin in the treatment of breast cancer Expert Rev. Anticancer Ther. 5 2005 591 604
112. E.E. Sander, S. van Delft, J.P. ten Klooster, T. Reid, R.A. van der Kammen, F. Michiels, and J.G. Collard Matrix-dependent Tiam1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase J. Cell. Biol. 143 1998 1385 1398
113. K. Scheffzek, M.R. Ahmadian, W. Kabsch, L. Wiesmuller, A. Lautwein, F. Schmitz, and A. Wittinghofer The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants Science 277 1997 333 337
114. M. Schwab Human neuroblastoma: from basic science to clinical debut of cellular oncogenes Naturwissenschaften 86 1999 71 78
115. T.N. Seagroves, H.E. Ryan, H. Lu, B.G. Wouters, M. Knapp, P. Thibault, K. Laderoute, and R.S. Johnson Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells Mol. Cell. Biol. 21 2001 3436 3444
116. R. Sears, F. Nuckolls, E. Haura, Y. Taya, K. Tamai, and J.R. Nevins Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability Genes Dev. 14 2000 2501 2514
117. R.C. Sears, and J.R. Nevins Signaling networks that link cell proliferation and cell fate J. Biol. Chem. 277 2002 11617 11620
118. T. Sebastian, R. Malik, S. Thomas, J. Sage, and P.F. Johnson C/EBPbeta cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence EMBO J. 24 2005 3301 3312
119. R. Shalom-Feuerstein, T. Cooks, A. Raz, and Y. Kloog Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells Cancer Res. 65 2005 7292 7300
120. B. Shi, B. Yaremko, G. Hajian, G. Terracina, W.R. Bishop, M. Liu, and L.L. Nielsen The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo Cancer Chemother. Pharmacol. 46 2000 387 393
121. J.M. Shields, K. Pruitt, A. McFall, A. Shaub, and C.J. Der Understanding Ras: 'it ain't over 'til it's over' Trends Cell. Biol. 10 2000 147 154
122. M. Shim, K.L. Powers, S.J. Ewing, S. Zhu, and R.C. Smart Diminished expression of C/EBPalpha in skin carcinomas is linked to oncogenic Ras and reexpression of C/EBPalpha in carcinoma cells inhibits proliferation Cancer Res. 65 2005 861 867
123. D.A. Sierra, S. Popov, and T.M. Wilkie Regulators of G-protein signaling in receptor complexes Trends Cardiovasc. Med. 10 2000 263 268
124. C. Sklar, J. Whitton, A. Mertens, M. Stovall, D. Green, N. Marina, B. Greffe, S. Wolden, and L. Robison Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study J. Clin. Endocrinol. Metab. 85 2000 3227 3232
125. A. Sodhi, S. Montaner, H. Miyazaki, and J.S. Gutkind MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF Biochem. Biophys. Res. Commun. 287 2001 292 300
126. J.H. Song, E.Y. So, and C.E. Lee Increased serine phosphorylation and activation of STAT1 by oncogenic Ras transfection Mol. Cells 13 2002 322 326
127. T. Sorlie Molecular portraits of breast cancer: tumour subtypes as distinct disease entities Eur. J. Cancer 40 2004 2667 2675
128. M. Stovall, S.S. Donaldson, R.E. Weathers, L.L. Robison, A.C. Mertens, J.F. Winther, J.H. Olsen, and J.D. Boice Jr. Genetic effects of radiotherapy for childhood cancer: gonadal dose reconstruction Int. J. Radiat. Oncol. Biol. Phys. 60 2004 542 552
129. N. Suzuki, K. Del Villar, and F. Tamanoi Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents Proc. Natl. Acad. Sci. U.S.A. 95 1998 10499 10504
130. W.F. Symmans, M. Ayers, E.A. Clark, J. Stec, K.R. Hess, and N. Sneige Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma Cancer 97 2003 2960 2971
131. H. Takeda, T. Matozaki, T. Takada, T. Noguchi, T. Yamao, M. Tsuda, F. Ochi, K. Fukunaga, K. Inagaki, and M. Kasuga PI 3-kinase gamma and protein kinase C-zeta mediate RAS-independent activation of MAP kinase by a Gi protein-coupled receptor EMBO J. 18 1999 386 395
132. D.H. Teng, R. Hu, H. Lin, T. Davis, D. Iliev, and C. Frye MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines Cancer Res. 57 1997 5221 5225
133. M. Toulany, K. Dittmann, M. Baumann, and H.P. Rodemann Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS Radiother. Oncol. 74 2005 117 129
134. D.L. Trump Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group Urol. Oncol. 23 2005 378 379
135. E. Van Cutsem, H. van de Velde, P. Karasek, H. Oettle, W.L. Vervenne, A. Szawlowski, P. Schoffski, S. Post, C. Verslype, H. Neumann, H. Safran, Y. Humblet, J. Perez Ruixo, Y. Ma, and D. Von Hoff Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J. Clin. Oncol. 22 2004 1430 1438
136. L.J. van't Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, and M. Mao Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
137. B. Vanhaesebroeck, S.J. Leevers, K. Ahmadi, J. Timms, R. Katso, P.C. Driscoll, R. Woscholski, P.J. Parker, and M.D. Waterfield Synthesis and function of 3-phosphorylated inositol lipids Annu. Rev. Biochem. 70 2001 535 602
138. D. Vordermark, and J.M. Brown Evaluation of hypoxia-inducible factor-1alpha (HIF-1alpha) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies Int. J. Radiat. Oncol. Biol. Phys. 56 2003 1184 1193
139. N.F. Watson, Z. Madjd, D. Scrimegour, I. Spendlove, I.O. Ellis, J.H. Scholefield, and L.G. Durrant Evidence that the p53 negative/Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients World J. Surg. Oncol. 3 2005 47
140. I.B. Weinstein Cancer. Addiction to oncogenes - the Achilles heal of cancer Science 297 2002 63 64
141. A.M. Winter-Vann, R.A. Baron, W. Wong, J. dela Cruz, J.D. York, D.M. Gooden, M.O. Bergo, S.G. Young, E.J. Toone, and P.J. Casey A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells Proc. Natl. Acad. Sci. U.S.A. 102 2005 4336 4341
142. M.P. Wymann, S. Sozzani, F. Altruda, A. Mantovani, and E. Hirsch Lipids on the move: phosphoinositide 3-kinases in leukocyte function Immunol. Today 21 2000 260 264
143. S. Yaari, J. Jacob-Hirsch, N. Amariglio, R. Haklai, G. Rechavi, and Y. Kloog Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest Clin. Cancer Res. 11 2005 4321 4330
144. S.X. Yang, R.M. Simon, A.R. Tan, D. Nguyen, and S.M. Swain Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer Clin. Cancer Res. 11 2005 6226 6232
145. M.T. Yip-Schneider, A. Lin, D. Barnard, C.J. Sweeney, and M.S. Marshall Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression Int. J. Oncol. 15 1999 271 279
146. D. Zagzag, D.R. Friedlander, B. Margolis, M. Grumet, G.L. Semenza, H. Zhong, J.W. Simons, J. Holash, S.J. Wiegand, and G.D. Yancopoulos Molecular events implicated in brain tumor angiogenesis and invasion Pediatr. Neurosurg. 33 2000 49 55
147. B.J. Zebrack, J.G. Gurney, K. Oeffinger, J. Whitton, R.J. Packer, A. Mertens, N. Turk, R. Castleberry, Z. Dreyer, L.L. Robison, and L.K. Zeltzer Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study J. Clin. Oncol. 22 2004 999 1006
148. B.J. Zebrack, L.K. Zeltzer, J. Whitton, A.C. Mertens, L. Odom, R. Berkow, and L.L. Robison Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma: a report from the Childhood Cancer Survivor Study Pediatrics 110 2002 42 52
149. S. Zimmermann, and K. Moelling Phosphorylation and regulation of Raf by Akt (protein kinase B) Science 286 1999 1741 1744